Pritelivir met its primary endpoint of superior lesion healing, achieving a 62.7% lesion healing rate compared to 34.0% with ...
A phase 3 trial finds pritelivir significantly improves cure rates for immunocompromised individuals with refractory HSV infections.
Innovative Molecules GmbH, a German clinical stage biotech company focused on development of novel agents in the field of ...
Full abstracts will be released on February 4, 2026, at 7:00 am CET/1:00 am EST and will be available via the conference website here .
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...
Clinical Trials Arena on MSN
AiCuris reports positive Phase III pritelivir results for HSV patients
The trial enrolled and treated 101 immunocompromised patients with refractory or resistant HSV infection.
FDA RMAT boosts inhaled gene therapy KB707, delivering IL‑2/IL‑12 to lung tumors; early trial shows responses with manageable ...
HHS Secretary Robert F. Kennedy Jr. named a new chairperson and 10 new public members to the federal Alzheimer's Advisory ...
The company’s sales grew 9.9% YoY – driven by a diverse range of portfolio classics and new launches.
SHELTON, CONNECTICUT / ACCESS Newswire / February 10, 2026 / NanoViricides, Inc., a publicly traded company (NYSE ...
Sustained interest in small molecules, bispecific antibodies, and genomics got the ball rolling in the biotech deals arena in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results